Clinical Trial ID: NCT06667076
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status
Open
Conditions
Other
Phases
2
Age Group
Adult
Main Investiagtor
Vu, John
Practice
Lung
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT06667076
Secondary Trial ID Number
2024-1619; 61186372NSC2012
Keywords
Treatment